** Biotech group Oxford Nanopore Technologies ONT.L up as much as 5.7% at 115.9p
** Gene sequencing specialist is now "exposed" to acquisition, CEO and co-founder Gordon Sanghera told FT
** ONT's shares have lost 85% since its peak in 2021
** "Bankers have said it could be attractive to one of the big diagnostics specialists, such as Thermo Fisher Scientific TMO.N or Danaher DHR.N," FT report adds
** As of last close, stock down ~15% this year
(Reporting by Radhika Anilkumar in Bengaluru)
((Radhika.Anilkumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。